A new meta-analysis of more than 6000 studies shows that oral contraceptives significantly reduce the risk of ovarian cancer. The risk reduction increases proportionally with duration of use.
See the abstract here
Related Topics
OCRA’s Advocate’s Corner: June 2025
Written by Chad Ramsey, Vice President, Policy, Ovarian Cancer Research Alliance FY26 Budget Update: Critical Cancer Programs at Risk Congress is deep into its work on the fiscal year 2026 … Continued
OCRA’s Advocate’s Corner: May 2025
FY26 Budget Watch, Advocacy Results, and State-Level Progress As Congress ramps up work on the FY26 federal budget, advocates are focused on maintaining vital cancer programs and advancing state policies … Continued
OCRA Sponsors NCCN 2025 Guidelines for Cervical Cancer Patients
This article was updated in May 2025 to reflect NCCN’s release of the 2025 Guidelines for Cervical Cancer Patients. OCRA is a proud sponsor of 2025 Cervical Cancer Updates. We … Continued